A Phase II, Open-Label Extension Study Evaluating the Long Term Safety, Tolerability ' Efficacy of Orally-Administered CYT387 in Primary Myelofibrosis or Post-Polycythemia Vera or Post-Essential Thrombocythemia Myelofibrosis
Latest Information Update: 13 Jun 2023
At a glance
- Drugs Momelotinib (Primary)
- Indications Myelofibrosis
- Focus Therapeutic Use
- Sponsors Gilead Sciences; Sierra Oncology
- 14 Jul 2014 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 20 Mar 2014 New trial record